Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B

Haruhiko Kobashi, Shin Ichi Fujioka, Mitsuhiko Kawaguchi, Hiromitsu Kumada, Osamu Yokosuka, Norio Hayashi, Kazuyuki Suzuki, Takeshi Okanoue, Michio Sata, Hirohito Tsubouchi, Chifumi Sato, Kendo Kiyosawa, Kyuichi Tanikawa, Taku Seriu, Hiroki Ishikawa, Akinobu Takaki, Yoshiaki Iwasaki, Toshiya Osawa, Toshiyuki Takaki, Kosaku Sakaguchi & 4 others Yasushi Shiratori, Kazuhide Yamamoto, Daniel J. Tenney, Masao Omata

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: Entecavir (ETV) is a potent nucleoside analogue against hepatitis B virus (HBV), and emergence of drug resistance is rare in nucleoside-naive patients because development of ETV resistance (ETVr) requires at least three amino acid substitutions in HBV reverse transcriptase. We observed two cases of genotypic ETVr with viral rebound and biochemical breakthrough during ETV treatment of nucleoside-naive patients with chronic hepatitis B (CHB). Results: Case1: A 44-year-old HBeAg-positive man received ETV 0.1 mg/day for 52 weeks and 0.5 mg/day for 96 weeks consecutively. HBV DNA was 10.0 log10 copies/ml at baseline, declined to a nadir of 3.1 at week 100, and rebounded to 4.5 at week 124 and 6.7 at week 148. Alanine aminotransferase (ALT) level increased to 112 IU/l at week 148. Switching to a lamivudine (LVD)/adefovir-dipivoxil combination was effective in decreasing HBV DNA. Case 2: A 47-year-old HBeAg-positive man received ETV 0.5 mg/day for 188 weeks. HBV DNA was 8.2 log10 copies/ml at baseline, declined to a nadir of 2.9 at week 124, and then rebounded to 4.7 at week 148 and 6.4 at week 160. ALT level increased to 72 IU/l at week 172. The ETVr-related substitution (S202G), along with LVD-resistance-related substitutions (L180M and M204V), was detected by sequence analysis at week 124 in both case 1 and case 2. Conclusions: ETVr emerged in two Japanese nucleoside-naive CHB patients after prolonged therapy and incomplete suppression and in one patient after

Original languageEnglish
Pages (from-to)403-410
Number of pages8
JournalHepatology International
Volume3
Issue number2
DOIs
Publication statusPublished - 2009

Fingerprint

Chronic Hepatitis B
Nucleosides
Hepatitis B virus
Hepatitis B e Antigens
Alanine Transaminase
DNA
Therapeutics
Lamivudine
RNA-Directed DNA Polymerase
Amino Acid Substitution
Drug Resistance
Sequence Analysis
entecavir

Keywords

  • Chronic hepatitis B
  • Drug resistance
  • Entecavir
  • HBV
  • Nucleoside-naive

ASJC Scopus subject areas

  • Hepatology

Cite this

Kobashi, H., Fujioka, S. I., Kawaguchi, M., Kumada, H., Yokosuka, O., Hayashi, N., ... Omata, M. (2009). Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B. Hepatology International, 3(2), 403-410. https://doi.org/10.1007/s12072-008-9108-8

Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B. / Kobashi, Haruhiko; Fujioka, Shin Ichi; Kawaguchi, Mitsuhiko; Kumada, Hiromitsu; Yokosuka, Osamu; Hayashi, Norio; Suzuki, Kazuyuki; Okanoue, Takeshi; Sata, Michio; Tsubouchi, Hirohito; Sato, Chifumi; Kiyosawa, Kendo; Tanikawa, Kyuichi; Seriu, Taku; Ishikawa, Hiroki; Takaki, Akinobu; Iwasaki, Yoshiaki; Osawa, Toshiya; Takaki, Toshiyuki; Sakaguchi, Kosaku; Shiratori, Yasushi; Yamamoto, Kazuhide; Tenney, Daniel J.; Omata, Masao.

In: Hepatology International, Vol. 3, No. 2, 2009, p. 403-410.

Research output: Contribution to journalArticle

Kobashi, H, Fujioka, SI, Kawaguchi, M, Kumada, H, Yokosuka, O, Hayashi, N, Suzuki, K, Okanoue, T, Sata, M, Tsubouchi, H, Sato, C, Kiyosawa, K, Tanikawa, K, Seriu, T, Ishikawa, H, Takaki, A, Iwasaki, Y, Osawa, T, Takaki, T, Sakaguchi, K, Shiratori, Y, Yamamoto, K, Tenney, DJ & Omata, M 2009, 'Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B', Hepatology International, vol. 3, no. 2, pp. 403-410. https://doi.org/10.1007/s12072-008-9108-8
Kobashi, Haruhiko ; Fujioka, Shin Ichi ; Kawaguchi, Mitsuhiko ; Kumada, Hiromitsu ; Yokosuka, Osamu ; Hayashi, Norio ; Suzuki, Kazuyuki ; Okanoue, Takeshi ; Sata, Michio ; Tsubouchi, Hirohito ; Sato, Chifumi ; Kiyosawa, Kendo ; Tanikawa, Kyuichi ; Seriu, Taku ; Ishikawa, Hiroki ; Takaki, Akinobu ; Iwasaki, Yoshiaki ; Osawa, Toshiya ; Takaki, Toshiyuki ; Sakaguchi, Kosaku ; Shiratori, Yasushi ; Yamamoto, Kazuhide ; Tenney, Daniel J. ; Omata, Masao. / Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B. In: Hepatology International. 2009 ; Vol. 3, No. 2. pp. 403-410.
@article{9b09d4bb93a5486abd96f25668cd03b5,
title = "Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B",
abstract = "Background: Entecavir (ETV) is a potent nucleoside analogue against hepatitis B virus (HBV), and emergence of drug resistance is rare in nucleoside-naive patients because development of ETV resistance (ETVr) requires at least three amino acid substitutions in HBV reverse transcriptase. We observed two cases of genotypic ETVr with viral rebound and biochemical breakthrough during ETV treatment of nucleoside-naive patients with chronic hepatitis B (CHB). Results: Case1: A 44-year-old HBeAg-positive man received ETV 0.1 mg/day for 52 weeks and 0.5 mg/day for 96 weeks consecutively. HBV DNA was 10.0 log10 copies/ml at baseline, declined to a nadir of 3.1 at week 100, and rebounded to 4.5 at week 124 and 6.7 at week 148. Alanine aminotransferase (ALT) level increased to 112 IU/l at week 148. Switching to a lamivudine (LVD)/adefovir-dipivoxil combination was effective in decreasing HBV DNA. Case 2: A 47-year-old HBeAg-positive man received ETV 0.5 mg/day for 188 weeks. HBV DNA was 8.2 log10 copies/ml at baseline, declined to a nadir of 2.9 at week 124, and then rebounded to 4.7 at week 148 and 6.4 at week 160. ALT level increased to 72 IU/l at week 172. The ETVr-related substitution (S202G), along with LVD-resistance-related substitutions (L180M and M204V), was detected by sequence analysis at week 124 in both case 1 and case 2. Conclusions: ETVr emerged in two Japanese nucleoside-naive CHB patients after prolonged therapy and incomplete suppression and in one patient after",
keywords = "Chronic hepatitis B, Drug resistance, Entecavir, HBV, Nucleoside-naive",
author = "Haruhiko Kobashi and Fujioka, {Shin Ichi} and Mitsuhiko Kawaguchi and Hiromitsu Kumada and Osamu Yokosuka and Norio Hayashi and Kazuyuki Suzuki and Takeshi Okanoue and Michio Sata and Hirohito Tsubouchi and Chifumi Sato and Kendo Kiyosawa and Kyuichi Tanikawa and Taku Seriu and Hiroki Ishikawa and Akinobu Takaki and Yoshiaki Iwasaki and Toshiya Osawa and Toshiyuki Takaki and Kosaku Sakaguchi and Yasushi Shiratori and Kazuhide Yamamoto and Tenney, {Daniel J.} and Masao Omata",
year = "2009",
doi = "10.1007/s12072-008-9108-8",
language = "English",
volume = "3",
pages = "403--410",
journal = "Hepatology International",
issn = "1936-0533",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B

AU - Kobashi, Haruhiko

AU - Fujioka, Shin Ichi

AU - Kawaguchi, Mitsuhiko

AU - Kumada, Hiromitsu

AU - Yokosuka, Osamu

AU - Hayashi, Norio

AU - Suzuki, Kazuyuki

AU - Okanoue, Takeshi

AU - Sata, Michio

AU - Tsubouchi, Hirohito

AU - Sato, Chifumi

AU - Kiyosawa, Kendo

AU - Tanikawa, Kyuichi

AU - Seriu, Taku

AU - Ishikawa, Hiroki

AU - Takaki, Akinobu

AU - Iwasaki, Yoshiaki

AU - Osawa, Toshiya

AU - Takaki, Toshiyuki

AU - Sakaguchi, Kosaku

AU - Shiratori, Yasushi

AU - Yamamoto, Kazuhide

AU - Tenney, Daniel J.

AU - Omata, Masao

PY - 2009

Y1 - 2009

N2 - Background: Entecavir (ETV) is a potent nucleoside analogue against hepatitis B virus (HBV), and emergence of drug resistance is rare in nucleoside-naive patients because development of ETV resistance (ETVr) requires at least three amino acid substitutions in HBV reverse transcriptase. We observed two cases of genotypic ETVr with viral rebound and biochemical breakthrough during ETV treatment of nucleoside-naive patients with chronic hepatitis B (CHB). Results: Case1: A 44-year-old HBeAg-positive man received ETV 0.1 mg/day for 52 weeks and 0.5 mg/day for 96 weeks consecutively. HBV DNA was 10.0 log10 copies/ml at baseline, declined to a nadir of 3.1 at week 100, and rebounded to 4.5 at week 124 and 6.7 at week 148. Alanine aminotransferase (ALT) level increased to 112 IU/l at week 148. Switching to a lamivudine (LVD)/adefovir-dipivoxil combination was effective in decreasing HBV DNA. Case 2: A 47-year-old HBeAg-positive man received ETV 0.5 mg/day for 188 weeks. HBV DNA was 8.2 log10 copies/ml at baseline, declined to a nadir of 2.9 at week 124, and then rebounded to 4.7 at week 148 and 6.4 at week 160. ALT level increased to 72 IU/l at week 172. The ETVr-related substitution (S202G), along with LVD-resistance-related substitutions (L180M and M204V), was detected by sequence analysis at week 124 in both case 1 and case 2. Conclusions: ETVr emerged in two Japanese nucleoside-naive CHB patients after prolonged therapy and incomplete suppression and in one patient after

AB - Background: Entecavir (ETV) is a potent nucleoside analogue against hepatitis B virus (HBV), and emergence of drug resistance is rare in nucleoside-naive patients because development of ETV resistance (ETVr) requires at least three amino acid substitutions in HBV reverse transcriptase. We observed two cases of genotypic ETVr with viral rebound and biochemical breakthrough during ETV treatment of nucleoside-naive patients with chronic hepatitis B (CHB). Results: Case1: A 44-year-old HBeAg-positive man received ETV 0.1 mg/day for 52 weeks and 0.5 mg/day for 96 weeks consecutively. HBV DNA was 10.0 log10 copies/ml at baseline, declined to a nadir of 3.1 at week 100, and rebounded to 4.5 at week 124 and 6.7 at week 148. Alanine aminotransferase (ALT) level increased to 112 IU/l at week 148. Switching to a lamivudine (LVD)/adefovir-dipivoxil combination was effective in decreasing HBV DNA. Case 2: A 47-year-old HBeAg-positive man received ETV 0.5 mg/day for 188 weeks. HBV DNA was 8.2 log10 copies/ml at baseline, declined to a nadir of 2.9 at week 124, and then rebounded to 4.7 at week 148 and 6.4 at week 160. ALT level increased to 72 IU/l at week 172. The ETVr-related substitution (S202G), along with LVD-resistance-related substitutions (L180M and M204V), was detected by sequence analysis at week 124 in both case 1 and case 2. Conclusions: ETVr emerged in two Japanese nucleoside-naive CHB patients after prolonged therapy and incomplete suppression and in one patient after

KW - Chronic hepatitis B

KW - Drug resistance

KW - Entecavir

KW - HBV

KW - Nucleoside-naive

UR - http://www.scopus.com/inward/record.url?scp=65049086668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65049086668&partnerID=8YFLogxK

U2 - 10.1007/s12072-008-9108-8

DO - 10.1007/s12072-008-9108-8

M3 - Article

VL - 3

SP - 403

EP - 410

JO - Hepatology International

JF - Hepatology International

SN - 1936-0533

IS - 2

ER -